Supernus Pharmaceuticals, Inc. reported $830M of revenue over the trailing twelve months, +25% on the year before. 11 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $830M (to Q2 2026). Net income: −$110M, trailing twelve months to Q2 2026. Free cash flow: $19M, trailing twelve months to Q2 2026. Operating margin: −16%, trailing twelve months to Q2 2026.

SUPNSupernus Pharmaceuticals, Inc.

Healthcare

$42.68-7.3% 1Y

$42.68

$41.3152 weeks$57.00

SUPN as reported

Supernus Pharmaceuticals, Inc. reported $830M of revenue over the trailing twelve months, +25% on the year before. 11 reported series are charted on this page, each one as filed.

$830M

Revenue, trailing twelve months · to Q2 2026 · +25% against the twelve months before

Net income: −$110M
Net income · −270% year on year · trailing twelve months to Q2 2026
Free cash flow: $19M
Free cash flow · −90% year on year · trailing twelve months to Q2 2026
Operating margin: −16%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for SUPN, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$830M	+25%	Q2 2026
Net income	−$110M	−270%	Q2 2026
EPS	−$1.92	−267%	Q2 2026
Gross margin	88%	n/a	Q2 2026
Operating margin	−16%	n/a	Q2 2026
Net margin	−13%	n/a	Q2 2026
ROE	−4.7%	n/a	Q2 2026
ROA	−3.4%	n/a	Q2 2026
ROIC	4.8%	n/a	Q1 2023 · 13 quarters behind
Free cash flow	$19M	−90%	Q2 2026
P/E	28.4	n/a	Q2 2025 · 4 quarters behind

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.